124 related articles for article (PubMed ID: 21855916)
1. Re: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. T. Maeda, E. Kikuchi, K. Matsumoto, A. Miyajima and M. Oya. J Urol 2011; 185: 802-806.
Serretta V
J Urol; 2011 Oct; 186(4):1557. PubMed ID: 21855916
[No Abstract] [Full Text] [Related]
2. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
[TBL] [Abstract][Full Text] [Related]
3. Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University of Michigan, Ann Arbor, MI.: J Urol 2012;188(6):2114-9. [Epub 2012 Oct 18]. doi: 10.1016/j.juro.2012.08.005.
Hollenbeck BK
Urol Oncol; 2014 Oct; 32(7):1089. PubMed ID: 25443143
[TBL] [Abstract][Full Text] [Related]
4. Re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
Garg M; Goel A; Prakash J
Eur Urol; 2013 Jan; 63(1):e6. PubMed ID: 23021089
[No Abstract] [Full Text] [Related]
5. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
Lee CT; Barocas D; Globe DR; Oefelein MG; Colayco DC; Bruno A; O'Day K; Bramley T
J Urol; 2012 Dec; 188(6):2114-9. PubMed ID: 23083857
[TBL] [Abstract][Full Text] [Related]
6. Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C.
Bryan RT
Eur Urol; 2012 Nov; 62(5):803-5. PubMed ID: 22728115
[No Abstract] [Full Text] [Related]
7. Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
Eur Urol; 2013 Jan; 63(1):e7-8. PubMed ID: 23092542
[No Abstract] [Full Text] [Related]
8. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
9. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
Aldemir M; Canda AE; Balbay MD
Eur Urol; 2010 Aug; 58(2):e23; author reply e24-5. PubMed ID: 20542629
[No Abstract] [Full Text] [Related]
10. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.
Geijsen ED; de Reijke TM; Koning CC; Zum Vörde Sive Vörding PJ; de la Rosette JJ; Rasch CR; van Os RM; Crezee J
J Urol; 2015 Nov; 194(5):1202-8. PubMed ID: 26143111
[TBL] [Abstract][Full Text] [Related]
11. Re: impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: M. Hagiwara, E. Kikuchi, N. Tanaka, K. Matsumoto, H. Ide, A. Miyajima, T. Masuda, S. Nakamura and M. Oya J Urol 2013; 189: 2062-2068.
Crivelli JJ; Xylinas E; Shariat SF
J Urol; 2014 Feb; 191(2):557-9. PubMed ID: 24239421
[No Abstract] [Full Text] [Related]
12. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R
Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768
[No Abstract] [Full Text] [Related]
13. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
14. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
15. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Mostafid AH; Rajkumar RG; Stewart AB; Singh R
BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
[TBL] [Abstract][Full Text] [Related]
16. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
17. [Intravesical instillation for bladder tumors].
Rivière A; Ploussard G; Desgranchamps F
Rev Prat; 2014 Dec; 64(10):1388-9. PubMed ID: 25665319
[No Abstract] [Full Text] [Related]
18. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Liberati E; Dutto L; Verri C
Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
[TBL] [Abstract][Full Text] [Related]
19. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Besarani D; Al-Akraa M
BJU Int; 2006 Jul; 98(1):232-3. PubMed ID: 16831177
[No Abstract] [Full Text] [Related]
20. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Shapiro O; Jones K; Wang C; Landas S; Haas GP
Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
